A revolutionary new prostate cancer test developed in Cambridge promises to redefine early detection, diagnosis, and personalised treatment. Designed by EDX Medical Group, this AI-driven test goes beyond conventional methods, offering unparalleled accuracy in identifying cancerous cells, gauging aggressiveness, and assessing genetic risk factors. With prostate cancer affecting tens of thousands annually in the UK and across Europe, this innovation has the potential to improve patient outcomes significantly.
By leveraging over 100 prostate-related biomarkers in blood and urine samples, the test provides a comprehensive picture of an individual’s cancer profile. Advanced AI algorithms assess early and late-stage cancer indicators, guiding more precise treatment strategies. Unlike current high-end tests, which rely on up to 20 biomarkers, this cutting-edge approach enhances sensitivity and specificity to an impressive 96-99%, ensuring reliable results across various age and ethnic groups.
The non-invasive nature of the test eliminates the need for unnecessary MRI scans and invasive rectal examinations, offering a more patient-friendly alternative. Its ‘multi-omics’ approach integrates multiple layers of biological data, including proteomic, transcriptomic, genetic, and epigenetic markers, providing a detailed insight into prostate cancer sub-types. Each biomarker has been rigorously validated in clinical trials involving over 31,000 positive prostate cancer cases and more than 100,000 non-cancer samples.
Developed in EDX Medical Group’s Cambridge laboratory, the test is now undergoing further validation as the company prepares for regulatory approval. A patent has already been filed for both the test and its AI algorithm, underscoring its potential as a game-changing innovation.
Professor Sir Chris Evans, founder and chief scientific officer of EDX Medical, believes the test will set a new benchmark in prostate cancer screening. The company anticipates launching the test by late 2025 or early 2026, ushering in a new era of precision diagnostics for men aged 45-70 and healthcare providers worldwide.
EDX Medical Group Plc (AQSE:EDX) is a global specialist in digital clinical diagnostics; developing and supporting high-performance products and services to provide cost-effective prediction of disease risk, inform clinical decision-making, enable personalised healthcare and accelerate the development of new medicines for cancer, neurology, heart disease and infectious diseases.
